Advances in current and emerging therapeutics for gestational trophoblast malignancies

References

• Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376:717–729.
   PubMed Web of Science ®Google Scholar
• Hertz R, Li MC, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med. 1956;93:361–366.
   PubMed Web of Science ®Google Scholar
• Ghorani E, Kaur B, Fisher RA, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet. 2017;390:2343–2345.
   PubMed Web of Science ®Google Scholar
• Vassilakos P, Riotton G, Kajii T. Hydatidiform mole: two entities. A morphological and cytogenetic study with some clinical considerations. Am J Obstet Gynecol. 1977;127:167–170.
   PubMed Web of Science ®Google Scholar
• Fowler DJ, Lindsay I, Seckl MJ, et al. Routine preevacuation ultrasound diagnosis of hydatidiform mole: experience of more than 1000 cases from a regional referral center. Ultrasound Obs Gynecol. 2006;27:56–60.
   PubMed Web of Science ®Google Scholar
• Savage PM, Sita-Lumsden A, Dickson S, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol. 2012;33:406–411.
   Google Scholar
• Atrash HK, Hogue CJ, Grimes DA. Epidemiology of hydatidiform mole during early gestation. Am J Obstet Gynecol. 1986;154:906–909.
   PubMed Web of Science ®Google Scholar
• Matsui H, Iitsuka Y, Yamazawa K, et al. Changes in the incidence of molar pregnancies. A population-based study in Chiba prefecture and Japan between 1974 and 2000. Hum Reprod. 2003;18:172–175.
   PubMed Web of Science ®Google Scholar
• Szulman AE, Surti U. The syndromes of hydatidiform mole. II. Morphologic evolution of the complete and partial mole. Am J Obstet Gynecol. 1978;132:20–27.
   PubMed Web of Science ®Google Scholar
• Wielsma S, Kerkmeijer L, Bekkers R, et al. Persistent trophoblast disease following partial molar pregnancy. Aust N Z J Obstet Gynaecol. 2006;46:119–123.
   PubMed Web of Science ®Google Scholar
• Sita-Lumsden A, Short D, Lindsay I, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009. Br J Cancer. 2012;107:1810–1814.
   PubMed Web of Science ®Google Scholar
• Elston CW. The histopathology of trophoblastic tumours. J Clin Pathol. 1976;29:111–131.
   PubMedGoogle Scholar
• Tidy JA, Rustin GJ, Newlands ES, et al. Presentation and management of choriocarcinoma after non-molar pregnancy. Br J Obstet Gynaecol. 1995;102:715–719.
   PubMedGoogle Scholar
• Mao TL, Kurman RJ, Huang CC, et al. Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis. Am J Surg Pathol. 2007;31:1726–1732.
   PubMed Web of Science ®Google Scholar
• Savage P, Seckl M, Short D. Practical issues in the management of low-risk gestational trophoblast tumors. J Reprod Med. 2008;53:774–780.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Young RH, Norris HJ, et al. Immunocytochemical localization of placental lactogen and chorionic gonadotropin in the normal placenta and trophoblastic tumors, with emphasis on intermediate trophoblast and the placental site trophoblastic tumor. Int J Gynecol Pathol. 1984;3:101–121.
   PubMed Web of Science ®Google Scholar
• Baergen RN, Rutgers JL, Young RH, et al. Placental site trophoblastic tumour: a study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol. 2006;100:511–520.
   PubMed Web of Science ®Google Scholar
• Schmid P, Nagai Y, Agarwal R, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet. 2009;374:48–55.
   PubMed Web of Science ®Google Scholar
• Bagshawe KD, McDonald JM. Treatment of choriocarcinoma with a combination of cytotoxic drugs. Br Med J. 1960;2:426–431.
   PubMedGoogle Scholar
• Bower M, Newlands ES, Holden L, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol. 1997;15:2636–2643.
   PubMed Web of Science ®Google Scholar
• Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 2013;31:280–286.
   PubMed Web of Science ®Google Scholar
• Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer. 1971;28:1479–1499.
   PubMed Web of Science ®Google Scholar
• Mitchison TJ. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell. 2012;23:1–6.
   PubMed Web of Science ®Google Scholar
• Savage P. Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential. BMC Cancer. 2015;15:11.
   PubMed Web of Science ®Google Scholar
• Savage P. Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesis. BMC Cancer. 2016;16:906.
   PubMed Web of Science ®Google Scholar
• FIGO staging for gestational trophoblastic neoplasia. FIGO oncology committee. Int J Gynaecol Obstet. 2000;2002(77):285–287.
   Google Scholar
• Ngan HY, Bender H, Benedet JL, et al. FIGO committee on gynecologic oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet. 2003;83(S1):175–177.
   PubMedGoogle Scholar
• Wang Q, Fu J, Hu L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2017;(9).
   Web of Science ®Google Scholar
• Bagshawe KD, Dent J, Newlands ES, et al. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol. 1989;96:795–802.
   PubMedGoogle Scholar
• Alazzam M, Tidy J, Hancock BW, et al. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2012 Jul 11;CD007102.
   PubMed Web of Science ®Google Scholar
• Deng L, Zhang J, Wu T, et al. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev. 2013;CD005196.
   PubMed Web of Science ®Google Scholar
• Newlands ES, Mulholland PJ, Holden L, et al. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol. 2000;18:854–859.
   PubMed Web of Science ®Google Scholar
• Wang J, Short D, Sebire NJ, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol. 2008;19:1578–1583.
   PubMed Web of Science ®Google Scholar
• Savage P, Kelpanides I, Tuthill M, et al. Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome. Gynecol Oncol. 2015;137:73–76.
   PubMed Web of Science ®Google Scholar
• Yordan EL Jr, Schlaerth J, Gaddis O, et al. Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system. Obstet Gynecol. 1987;69:627–630.
   PubMed Web of Science ®Google Scholar
• Seckl MJ, Sebire NJ, Fisher RA, et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi39–50.
   PubMed Web of Science ®Google Scholar
• Bolze PA, Riedl C, Massardier J, et al. Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥13. Am J Obstet Gynecol. 2016;214:390.e1-8.
   PubMed Web of Science ®Google Scholar
• Kong Y, Yang J, Jiang F, et al. Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: a retrospective cohort study. Gynecol Oncol. 2017;146:81–86.
   PubMed Web of Science ®Google Scholar
• Ahamed E, Short D, North B, et al. Survival of women with gestational trophoblastic neoplasia and liver metastases: is it improving? J Reprod Med. 2012;57:262–269.
   PubMed Web of Science ®Google Scholar
• El-Helw LM, Seckl MJ, Haynes R, et al. High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. Br J Cancer. 2005;93:620–621.
   PubMed Web of Science ®Google Scholar
• Frijstein M, Lok C, Short D, et al. The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for Gestational Trophoblastic Neoplasia. (submitted).
   Google Scholar
• Fisher RA, Savage PM, MacDermott C, et al. The impact of molecular genetic diagnosis on the management of women with hCG-producing malignancies. Gynecol Oncol. 2007;107:413–419.
   PubMed Web of Science ®Google Scholar
• Powles T, Savage PM, Stebbing J, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer. 2007;96:732–737.
   PubMed Web of Science ®Google Scholar
• Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship–genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98:15–25.
   PubMed Web of Science ®Google Scholar
• Savage P, Cooke R, O’Nions J, et al. Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. J Clin Oncol. 2015;33:472–478.
   PubMed Web of Science ®Google Scholar
• Moffett A, Chazara O, Colucci F. Maternal allo-recognition of the fetus. Fertil Steril. 2017;107:1269–1272.
   PubMed Web of Science ®Google Scholar
• Hunt J, Langat D. HLA-G: a human pregnancy-related immunomodulator. Curr Opin Pharmacol. 2009;9:462–469.
   PubMed Web of Science ®Google Scholar
• Veras E, Kurman RJ, Wang T-L, et al. PD-L1 expression in human placentas and gestational trophoblastic diseases. Int J Gynecol Pathol. 2017;36:146–153.
   PubMed Web of Science ®Google Scholar
• Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8.
   PubMed Web of Science ®Google Scholar
• Worley MJ Jr, Elias KM, Horowitz NS, et al. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: a case from the New England Trophoblastic Disease Center, Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Gynecol Oncol. 2018;148:5–11.
   PubMed Web of Science ®Google Scholar
• Available from: https://isstd.org/
   Google Scholar